GlassScriptPhysician profile
Bhanu Sud
NPI 1972643344
$37,379.70
in general payments reported to CMS, 2019-2025
23 companies · $4,821 in 2025
The $4,821 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,045 · 2020: $6,881 · 2021: $1,853 · 2022: $3,141 · 2023: $5,342 · 2024: $6,298 · 2025: $4,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,709 · Education: $260 · Travel and Lodging: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,300.00 |
| Food and Beverage | $3,709.25 |
| Education | $259.69 |
| Travel and Lodging | $191.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,417.13 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Allergan, INC. | $14,683.20 | 2019-2020 | |
| Viiv Healthcare Company | $1,180.91 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $951.68 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Gilead Sciences, INC. | $854.58 | 2019-2025 | Veklury |
| Insmed, INC. | $384.30 | 2022-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $356.39 | 2020-2023 | Symtuza |
| Melinta Therapeutics, LLC | $333.91 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Accelerate Diagnostics INC. | $251.79 | 2019 | |
| Shionogi INC | $248.29 | 2021-2025 | Fetroja |
| Astellas Pharma US INC | $122.92 | 2019-2024 | |
| Cumberland Pharmaceuticals, INC. | $119.65 | 2019-2023 | Caldolor, Vibativ |
| Theratechnologies INC. | $111.91 | 2022-2024 | Trogarzo, Egrifta |
| Philips North America LLC | $84.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.70 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $53.17 | 2024-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $33.58 | 2024 | Cuvitru |
| Ferring Pharmaceuticals INC. | $27.22 | 2022 | |
| Dynavax Technologies Corporation | $27.01 | 2019 | |
| Vyera Pharmaceuticals, LLC | $20.38 | 2020 | |
| Mayne Pharma Commercial LLC | $20.28 | 2022 | |
| Nabriva Therapeutics, Plc | $19.29 | 2022 | |
| Napo Pharmaceuticals INC | $17.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhanu Sud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.